期刊文献+

雷公藤多甙与环磷酰胺分别联合泼尼松治疗特发性膜性肾病疗效比较 被引量:10

Efficacy comparison of Tripterygium Wilfordii Polyglycoside and Cyclophosphamide combined with prednisone treatment on idiopathic membranous nephropathy
原文传递
导出
摘要 【目的】观察雷公藤多甙(tripterygium wilfordii,TW)与环磷酰胺(cyclophosphamide,CTX)分别联合泼尼松(prednisone,PED)治疗特发性膜性肾病(idiopathic membranous nephropathy,IMN)的疗效、复发率等差异。【方法】对随访的经TW+PED治疗组[分3次口服TW 2 mg.(kg.d)-1,缓解后减量维持,6个月无效者停药,同时口服PED 0.5~1 mg.(kg.d)-1,8周后逐渐减量]和经CTX+PED治疗组[静脉滴注CTX 0.5~1.0 g.(m2.m)-1,1次/月,共6个月,此后每3个月1次,累计剂量8~10 g,同时口服PED0.5~1 mg.(kg.d)-1,8周后逐渐减量]定期检测尿蛋白定量、血清白蛋白、肝肾功能等指标,对患者治疗期间的疾病缓解率、复发率等进行观察。【结果】两组尿蛋白定量及血浆白蛋白水平较治疗前明显好转(P<0.05),治疗前后肝肾功能未见明显变化,TW+PED治疗组患者最大缓解率出现在约第6个月;CTX+PED治疗组患者最大缓解率出现在约第12个月,两组总缓解率无统计学差异(P>0.05)。TW+PED组患者复发出现在约第12个月;CTX+PED治疗组患者复发出现在约第18个月,CTX+PED治疗组复发率明显低于TW+PED治疗组(P<0.05)。【结论】两种治疗方法对IMN均有一定的疗效。TW+PED方法和CTX+PED方法相比较,前者患者的病情缓解发生早于后者,在总缓解率方面两者之间不存在明显的差异,但前者短期的复发率要高于后者。对于两种治疗方法的远期效果及患者肾功能的进展,仍需进一步的长期随访观察。 【Objective】 To evaluate the efficacy and recurrent rate of Tripterygium Wilfordii Polyglycoside(TW)and Cyclophosphamide(CTX)in combination with Prednisone(PED)in the treatment on idiopathic membranous nephropathy(IMN).【Method】 Patients diagnosed as IMN by renal biopsy were treated TW [2 mg·(kg·d)-1,tid,if remitted,the dose was decreased for maintenance treatment,if no efficiency was observed after 6 months,TW should not be administrated.Prednisone 0.5~1 mg·(kg·d)-1 was administered concomitantly] and CTX 0.5~1.0 g·(m2·m)-1,administered via intravenous route every month for 6 months,subsequently administered every three months,8~10 g in total.Prednisone [0.5~1 mg·(kg·d)-1 was administered concomitantly].Urine protein quantification,serum albumin,hepatatic and renal function were measured regularly.The remission rate and recurrent rate were evaluated during treatment.【Results】 Urine protein quantification and serum albumin after treatment were improved as compared those before treatment(P 〈 0.05),no significant difference in hapatatic and renal function was found between two groups before and after treatment.The peak remission rate in TW group was observed in 3~6 months after treatment,which was observed in CTX group in 12 months after treatment,there was no statistical difference between two groups(P 〉 0.05).The trough recurrence rate in TW group was observed around 12 months after treatment,which was observed in CTX group in 18 months after treatment.The recurrence rate in CTX group was signific-two groups,but the short term remissionrate in TW group is higher than that in CTX group.The long term efficiency and effect on renal function progress of both dugs to IMN patients were needed to further follow up.
出处 《武警后勤学院学报(医学版)》 CAS 2012年第9期678-681,F0003,共5页 Journal of Logistics University of PAP(Medical Sciences)
关键词 特发性膜性肾病 雷公藤多甙 环磷酰胺 Idiopathic membranous nephropathy Tripterygium Wilfordii Cyclophosphamide
  • 相关文献

参考文献16

  • 1Moranne O,Watier L,Rossert J. Primary glomerulonephritis:an update on renal survival anddeterminants of progression[J].Quarterly Journal of Medicine,2008,(03):215-224.doi:10.1093/qjmed/hcm142.
  • 2Wasserstein AG. Membranous glomerulonephritis[J].Journal of the American Society of Nephrology,1997,(04):664-674.
  • 3Donadio JV,Torres VE,Velosa JA. Idiopathic membranous nephropathy:the natural history of untreated patients[J].Kidney International,1988,(03):708-715.
  • 4Couser WG. Membranous nephropathy:a long road but well traveled[J].Journal of the American Society of Nephrology,2005,(05):1184-1187.
  • 5Ronco P,Debiec H. Molecular pathomechanisms of membranous nephropathy:from Heymann nephritis to alloimmunization[J].Journal of the American Society of Nephrology,2005,(05):1205-1213.
  • 6Nangaku M,Shankland SJ,Couser WG. Celluar response to injury in membranous nephropathy[J].Journal of the American Society of Nephrology,2005,(05):1195-1204.
  • 7Cunningham PN,Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy[J].Journal of the American Society of Nephrology,2005,(05):1214-1222.
  • 8张景红.膜性肾病的免疫抑制治疗[J].中国中西医结合肾病杂志,2008,9(11):941-945. 被引量:10
  • 9Jha V,Ganguli A,Saha TK. A Randomized,controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous Nephropathy[J].Journal of the American Society of Nephrology,2007,(06):1899-1904.doi:10.1681/ASN.2007020166.
  • 10Ponticelli C,Altieri P,Scolari F. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy[J].Journal of the American Society of Nephrology,1998,(03):444-450.

二级参考文献57

  • 1王琳,陈以平,邓跃毅,张春崧,金亚明,沈玲妹,朱戎,钟逸斐.益气活血化湿方案为主治疗膜性肾病临床分析[J].中国中西医结合肾病杂志,2006,7(8):393-396. 被引量:36
  • 2秦卫松,刘志红,曾彩虹,郑春霞,贾忠辉,王生余,黎磊石.雷公藤甲素对Heymann肾炎模型足细胞病变的影响[J].肾脏病与透析肾移植杂志,2007,16(2):101-109. 被引量:97
  • 3黎磊石 张训 等.雷公藤治疗肾炎的临床与实验研究[J].中华医学杂志,1982,62:81-81.
  • 4黎磊石 张训.雷公藤治疗肾小球肾炎的临床研究[J].中华内科杂志,1981,20:216-216.
  • 5Lai KN. Membranous nephropathy: When and how to treat. Kidney Int,2007,71(9) :841 - 843.
  • 6Schieppati A, Pema A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev, 2004, 18(4) : CD004293.
  • 7Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrcnocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis,2006,47(2) :233 - 240.
  • 8Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syn- drome caused by idiopathic membranous nephropathy. J Am Soc Nephrol,2007,18(6) :1899 - 1904.
  • 9du Bur - Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy:outline and rationale of a treatment strategy. Am J Kid Dis, 2005,46(6):1012 - 1029.
  • 10Goumenos DS, Katopodis KP, Passadakis P, et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol,2007,27(3):226 - 231.

共引文献80

同被引文献173

  • 1张菊.昆仙胶囊治疗肾病综合征疗效及对患者血清IFN-γ和IL-21水平的影响[J].陕西医学杂志,2020,49(3):345-348. 被引量:11
  • 2邵凤,王广基,孙建国,谢海棠,张荣,诸晓燕.雷公藤内酯醇在Beagle犬体内的药代动力学[J].药学学报,2007,42(1):61-65. 被引量:17
  • 3秦卫松,刘志红,曾彩虹,郑春霞,贾忠辉,王生余,黎磊石.雷公藤甲素对Heymann肾炎模型足细胞病变的影响[J].肾脏病与透析肾移植杂志,2007,16(2):101-109. 被引量:97
  • 4陈朝红,刘志红,孙骅,姚根宏,秦卫松,黎磊石.雷公藤甲素干预足细胞病变的体外观察[J].肾脏病与透析肾移植杂志,2007,16(2):119-126. 被引量:45
  • 5du Bur-Vereijken PW, Branten AJ, Wetzels JF, et al. Cyto- toxic therapy for membranous nephropathy and renal in- sufficiency:improved renal survival but high relapse rate [J]. Nephrol Dial Transplant,2004,19 (5) .. 1142-1148.
  • 6Quaglia M,Stratta P. Idiopathic membranous nephropathy : manage.ment strategies [J]. Drugs ,2009,69 (10) :1303-1317.
  • 7Cameron JS,Healy MJ,Adu D. The Medical Research Council trialof short-term high-dose alternate day prednisolone in idiopathicmembranous nephropathy with nephritic syndrome in adults. TheMRC Glomerulonephritis Working Party[J]. Q J Med, 1990,74(274):133-156.
  • 8Ponticelli C,Zucchelli P,Passerini P,e. al. A 10-year follow-up of arandomized study with methylprednisolone and chlorambueii inmembranous nephropathy[J]. Kidney Int, 1995,48(5) :1600-1604.
  • 9Howman A,Chapman TL,Tangdon MM,et al. Immunosuppressionfor progressive membranous nephropathy: a UK randomised con-trolled trial[J]. Lancet,2013,381 .9868) :744-751.
  • 10Ponticelli C,Altieri P,Scolari Y,et al. A randomized study compa-ring methylprednisolone plus chlorambucil versus methylprednisolo-ne plus cyclophosphamide in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 1998,9(3) :444-450.

引证文献10

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部